Sector News

Wren Therapeutics raises £12.4m in latest financing round

January 31, 2021
Life sciences

Cambridge, UK-based biopharmaceutical company Wren Therapeutics has completed the closing of £12.4m financing, taking its total capital raised to date to around £33m.

The latest financing round was led by the company’s existing shareholder The Baupost Group, with new investors including Schooner Capital and Industry Ventures. Other existing investors, including LifeForce Capital, also participated.

Wren, a spin-off company from both the University of Cambridge in the UK and Lund University in Sweden, is focused on drug discovery and development for the treatment of protein misfolding diseases.

The company has utilised the capital raised so far to advance its lead small molecule programmes, targeting amyloid-beta and alpha-synuclein – with the first clinical candidate for amyloid-β set for Q1 2021.

Last December, Wren also signed a research collaboration agreement with Eisai to discover new small molecules for the potential treatment of synucleinopathies.

Synucleinopathies are neurodegenerative disease characterised by the misfolding and aggregation of a-synuclein in neurons and glial cells.

This includes Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy.

Wren has also expanded its pipeline to included three additional targets – including IAAP for diabetes, tua for Alzheimer’s disease and other tauopathies, and TDP-43 for motor neurone disease.

“The new capital, alongside our recently announced collaboration with Eisai, is a further endorsement of our unique chemical kinetics platform that has been industrialised by the Wren team over the previous four years, building on more than a decade of prior academic research,” said Samuel Cohen, chief executive officer of Wren.

“Our mission is to radically advance drug discovery for a wide range of protein misfolding diseases by creating molecules that will offer transformative therapeutic options for millions of patients globally suffering from these increasingly common medical disorders,” he added.

by Lucy Parsons

Source: pharmatimes.com

Related News

February 28, 2021

UCB taps Microsoft to accelerate drug discovery, clinical trials

Life sciences

The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.

February 28, 2021

GSK to close two UK antibiotics manufacturing sites

Life sciences

The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.

February 28, 2021

Colorcon launches TiO2-free supplement coating

Life sciences

“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.

Send this to a friend